Physician profile
Ericka Taylor-Daniel
NPI 1992186142
$39,481.47
in general payments reported to CMS, 2019-2025
28 companies · $6,932 in 2025
The $6,932 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $2,071 · 2023: $22K · 2024: $7,643 · 2025: $6,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $5,764 · Travel and Lodging: $3,817 · Consulting Fee: $1,880 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,500.00 |
| Food and Beverage | $5,763.75 |
| Travel and Lodging | $3,816.66 |
| Consulting Fee | $1,880.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34,199.35 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $794.68 | 2022-2025 | Spravato, Invega, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $759.04 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $699.54 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $672.13 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $462.99 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $296.92 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $220.29 | 2021-2025 | Caplyta |
| Corium, LLC | $195.43 | 2023-2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $139.76 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $115.12 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $113.32 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $107.67 | 2024-2025 | Trintellix |
| Gilead Sciences, INC. | $107.61 | 2021-2025 | Descovy |
| Axsome Therapeutics, INC. | $101.63 | 2024-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $85.37 | 2021-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $82.50 | 2023-2025 | Qelbree, Qelbree |
| Novo Nordisk INC | $57.63 | 2023-2025 | Wegovy |
| Smith+Nephew, INC. | $42.71 | 2024 | Collagenase Santyl |
| Watermark Medical, INC. | $40.16 | 2024 | |
| Braeburn INC. | $35.01 | 2023-2024 | Brixadi |
| Sunovion Pharmaceuticals INC. | $29.59 | 2022 | |
| Lilly USA, LLC | $25.07 | 2025 | Mounjaro |
| Shield Therapeutics INC | $24.34 | 2023 | Accrufer |
| Noven Therapeutics, LLC | $19.61 | 2024 | Xelstrym |
| Astrazeneca Pharmaceuticals LP | $19.60 | 2025 | Airsupra |
| Viiv Healthcare Company | $19.50 | 2023 | Apretude |
| Currax Pharmaceuticals LLC | $14.90 | 2025 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ericka Taylor-Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.